Colorectal cancer is one of the major causes of death from cancer. Metastasis is the leading cause of treatment failure, in which cancer stem cells and circulating tumor cells play crucial roles. Identifying the involved metastatic biomarkers and clarifying the regulation mechanisms are of great importance for targeting tumor metastasis. In the current research, we discovered that KIAA1199, a cell-migration inducing protein, showed higher expression in CD441 cancer cells from metastatic compared with the paired primary tissues, and was upregulated in colorectal cancer and positively correlated with numbers and mesenchymal phenotype of circulating tumor cells, and predicted shorter progress-free survival. Moreover, we indicated that down-regulation of KIAA1199 suppressed migration and invasion of colorectal cancer cells in vitro, and inhibited metastasis in vivo. Furthermore, we demonstrated that KIAA1199 was one of the direct and functional targets of miR-216a, and miR-216a overexpression led to decreased migration and invasion of colorectal cancer cells in vitro, and inhibited metastasis in vivo. Collectively, KIAA1199 plays a critical role in maintaining an aggressive phenotype of tumor cells, and suppression of KIAA1199-related motilities of tumor cells contributes to reduced tumor metastasis in colorectal cancer.
early stage is >90%, while <10% for patients diagnosed in advanced stage. 3, 4 Tumor metastasis is a multistep process with multiple genes involved in, tumor cells experienced detachment from the primary tumor, epithelial to mesenchymal transition (EMT), invasion through the extracellular matrix and blood vessels, dissemination into circulation, traveling through the bloodstream or the lymphatic system, extravasating into distant tissues, surviving in foreign microenvironments and generating metastases. [5] [6] [7] Yet the process remains one of the most enigmatic aspects of the disease, therefore, it is imperative to explore novel mechanisms of tumor metastasis.
Cancer stem cells (CSC) or cancer stem-like cells are the "seed" cells responsible for tumorigenesis, tumor metastasis, resistance against chemotherapy and radiotherapy and tumor recurrence. 8, 9 However, the mechanism of CSC mediated metastasis has not been fully elucidated. According to the recent reports, some genes in cancer stem cells were differentially expressed between metastatic and primary CRC tissues. 8, 10 Detection of these genes, investigation of the effects on tumor metastasis and exploration of the potential mechanisms are of great importance to develop novel therapeutics for CSC related metastasis.
CD44 and CD133 were proposed to be putative surface markers of colorectal cancer stem cells, which played important roles in tumor metastasis. [11] [12] [13] [14] CD441 cancer cells displayed higher clonal formation capacities in vitro, robust tumorigenicity in xenograft model as well as high metastatic potential. 15 Notably, it was found that knockdown of CD44, but not CD133, remarkably inhibited clone formation and tumorigenesis of CRC cells. 16 CD44 was also reported to be a transmembrane glycoprotein, which played a role in cancer cell migration and adhesion, thereby involving in cellular aggregation and tumor aggression. 17 It is well established that circulating tumor cells (CTCs) as "liquid biopsies," possess prosperities to prognosticate disease and guide treatment in many cancers. [18] [19] [20] [21] One of the key approaches of tumor metastasis in CRC is hematogenous metastasis, in which CTCs play important roles. Circulating tumor microemboli (CTM) described as "collective migration" was reported to have 23-to 50-fold increased metastatic potential than CTCs. 22, 23 Meanwhile, EMT process endows cells with migratory and invasive properties. 24 Thus CTM and EMT CTCs were expected to carry even more promising clinical use.
The expression of gene was regulated by numerous factors. Recently, mounting researches have demonstrated that microRNAs (miRNAs) are crucial regulators of translational control in gene expression. 25 miRNAs mediate the instability and degradation of target genes by binding to their 3 0 untranslated region (3 0 -UTR). 26 Human miRNAs genes were reported to be frequently located at cancer-associated genomic regions or fragile sites involved in malignancies, 27 participating in various biological processes, such as proliferation, differentiation, apoptosis and migration. 28, 29 Although many researches have investigated the function of miRNAs in a variety of cancers, the role of miRNAs in metastatic process, especially in CRC, has not been fully elucidated before.
In the current research, we detect the metastasis-related genes differentially expressed in CD441 cancer cells from metastatic and primary CRC tissues, and identify KIAA1199 to be significantly up-regulated in metastatic CRC tissues. We demonstrate that down-regulation of KIAA1199 reduce tumor invasion metastasis in CRC, and KIAA1199 is a direct and functional target of miR-216a. Metastasis is the leading cause of treatment failure in colorectal cancer (CRC). Here, the authors found that KIAA1199, a cellmigration inducing protein, was more highly expressed in CD441 cancer cells from metastatic CRC tissues compared with paired primary CRC tissues. KIAA1199 was up-regulated in CRC, correlated positively with circulating tumor cells and predicted poor survival. KIAA1199 down-regulation suppressed invasion and metastasis of CRC cells. In particular, miR-216a directly targeted KIAA1199 and led to decreased invasion and metastasis. The data suggest that KIAA1199 plays a critical role in maintaining an aggressive phenotype and targeting KIAA1199 could reduce tumor metastasis in CRC.
Material and Methods

Reagents and antibodies
Shanghai, China) and were cultured in DMEM or RPMI 1640 (GIBCO) supplemented with 10% fetal bovine serum (FBS; GIBCO), 100 U/mL penicillin and 100 lg/mL streptomycin. Human colon epithelial cell FHC was purchased from ATCC (Manassas, VA) and cultured under conditions specified by the supplier.
Immunohistochemistry analysis
Refer to the Supporting Information Material and Methods.
Vectors and lentiviral infection
Migration assays, invasion assays and three-dimensional invasion assay
Western blotting
Quantitative RT-PCR analysis
Immunofluorescence assay and CTC/CTM staining
Dual-luciferase reporter assays
In vivo metastasis analysis
All treatments were performed under the guidelines of our Institutional Animal Care and Use Committee. Two stable cell lines (HCT116-KIAA1199 shRNA-GFP and HCT116-Luc shRNA-GFP) and HCT116-miR-216a mimic and HCT116-control mimic cells, were injected into NOD/SCID mice (5 weeks old, female, 14-16 g, Vital River Laboratory Animal Technology Co. Ltd., China) at a final concentration of 1.5 3 10 6 cells/100 lL via tail vein to imitate tumor metastasis (n 5 7). Body weight were monitored twice a week. Mice were sacrificed after 45 days, lung tissues were first imaged by bioluminescence (Caliper Life Sciences, IVIS Lumina XR system), and were then fixed in 4% buffered formalin for hematoxylineosin (H&E) staining and immunohistochemistry staining.
Statistical analysis
Statistically analysis was performed using SPSS16.0 (SPSS Inc., Chicago, IL). The statistical significance between groups was determined by Student's t test or one-way ANOVA with Dunnett's t test. The correlation between KIAA1199 expression and clinicopathological features was analyzed by the v 2 -test. Association of patient survival probability with KIAA1199 expression was determined by Kaplan-Meier analysis and Log-rank test. Prognostic factors were investigated with the univariate Cox regression model and subsequently with the multivariate Cox regression model. Correlation between the expression of KIAA1199 and microRNAs were analyzed by the Spearman correlation coefficient. Data were presented as means 6 SEM. p < 0.05 was considered statistically significant.
Results
Upregulation of KIAA1199 in human CRC predicted poor prognosis
To detect the potential genes which would contribute to CRC metastasis, we initially collected fresh tissues of human primary colon carcinoma and metastatic lymph nodes from three patients (Supporting Information Table S1 ). CD452/CD441 cancer cells were obtained through flow cytometry cell sorting (FACS; Supporting Information Fig. S1A ), total RNA was isolated and performed gene chips analysis to search the potential differentially expressed genes. As shown in Figure 1a and Supporting Information Table S2 , we identified nine metastasisrelated genes (STC2, JUB, KIAA1199, SLC38A2, ALCAM, BNIP3, RCAN1, CTCF, SMARCA5) differentially expressed in CD441 cancer cells from primary and metastatic CRC tissues. KIAA1199 has been reported to be a cell-migration inducing protein (CEMIP) that involved in migration and invasion of tumor cells, therefore, it was chosen for the subsequent confirmation study. Real-time PCR results indicated that KIAA1199 was indeed overexpressed in CD441 cancer cells from metastasis compared with the paired primary tissues (Fig. 1b , Supporting Information Table S3 ). KIAA1199 was evaluated once again in another 19 pairs of CRC tissues by immunohistochemistry (IHC) staining. KIAA1199 showed higher expression in metastases compared with primary colorectal carcinoma, and also showed higher expression in primary colorectal carcinoma compared with adjacent paracancerous tissues (Fig. 1c , Supporting Information Table S4 ). To further confirm the candidate gene, the relationships between KIAA1199 expression and clinicopathological features and patients' survival were also evaluated. Notably, patients with higher invasion depth and TNM stage displayed higher KIAA1199 expression (Supporting Information Table S5 , and Fig. S1B , C), KIAA1199 expression had positive correlation with invasion depth and TNM stage (Fig. 1d, Table 1 ), and was an poor prognostic factor for progress-free survival (PFS) in CRC (Fig. 1e , Supporting Information Table S6 ). Therefore, these data demonstrated that upregulated KIAA1199 expression might be an important factor which can induce CRC metastasis and predict poor prognosis. of mesenchymal phenotype (cytokeratin-/vimentin1/CD452). We next detected KIAA1199 expression in CRC tissues by IHC, it indicated that KIAA1199 showed higher expression in CTCs/ CTM1 compared with CTCs/CTM-group (Fig. 1h) , though no significant difference was observed in KIAA1199 expression between CTCs1 and CTM1 group. Besides, KIAA1199 showed higher expression in cytokeratin1 compared with CTCs/CTMgroup, and more importantly, KIAA1199 showed higher expression in vimentin1 compared with cytokeratin1 group (Fig. 1h) . We performed v 2 -test to elucidate the correlation between KIAA1199 expression and CTCs/CTM. As Shown in Supporting Information Table S7, KIAA1199 high was positively correlated with CTCs/CTM1, CTM1 and vimentin1. Collectively, we demonstrated that KIAA1199 expression was significantly correlated with numbers and mesenchymal phenotype of CTCs/CTM.
KIAA1199 induced migration and invasion of CRC cells in vitro
To investigate the effects of KIAA1199 on the migration and invasion potential of CRC cells, we first surveyed KIAA1199 expression in cell lines derived from different tissues. Data in Figure 2a (left) and Supporting Information Figure S2A showed that KIAA1199 mRNA and protein were observed to increase gradually from human normal colon epithelial cell (FHC) to human primary CRC cells (HCT116 and HT29) and, ultimately, to cells derived from colorectal metastatic site (LOVO and SW620). Similar results were observed in CD441 CRC cells (Fig. 2a, right) . Then KIAA1199 was knocked down or overexpressed by transfecting KIAA1199 shRNA (Supporting Information Fig. S2B ) or KIAA1199 cDNA. As expected, knock-down of KIAA1199 remarkably inhibited the migratory and invasive ability of HCT116 and LOVO cells, as examined by a transwell migration and invasion assay (Fig. 2b and Supporting Information Fig. S2C ). Besides, we aslo examined the function of KIAA1199 in cancer invasion using a three-dimensional (3D) invasion assay, and the results indicated that knock-down of KIAA1199 abrogated invasion of HCT116 and LOVO cells (Fig. 2c) . Meanwhile, the migratory and invasive capabilities were rescued by overexpression of KIAA1199 in the silenced cells ( Fig. 2d and Supporting Information Fig. S2D ). Similar result was observed in 3D invasion assay (Fig. 2c) . Collectively, these results suggested that KIAA1199 enhanced migration and invasion of CRC cells in vitro.
KIAA1199 improved EMT of CRC cells
Because decreased cell migration often due to EMT phenotypic changes, we next examined the change of cell morphology and EMT-related markers. Indeed, we observed morphological changes of KIAA1199 down-regulated CRC cells from a mesenchymal-like shape to a polarized epithelial-like shape. Staining of filamentous actin (F-actin) was in consonance with morphological changes (Fig. 2e) . Furthermore, knock-down of KIAA1199 increased expression of epithelial marker (E-cadherin and Cytokeratin 8, 18, 19) and decreased expression of mesenchymal markers (vimentin and Twist-1). Conversely, overexpression of KIAA1199 degraded the expression of Cytokeratin 8, 18, 19 and elevated the expression of Twist-1 ( Fig. 1f and Supporting Information Fig. S2E ). These results indicated that KIAA1199 encouraged EMT in CRC cells. Additionally, we found that downregulation of KIAA1199 significantly decreased CD441 cell population in CRC cells (Supporting Information Fig. S3 ).
Downregulation of KIAA1199 attenuated tumor metastasis in CRC
It has been widely accepted that enhanced cell invasion promoted tumor metastasis. 30, 31 To evaluate the function of KIAA1199 on CRC metastasis in vivo, stable cell lines (HCT116-KIAA1199 shRNA-GFP and HCT116-Luc shRNA-GFP) were established using lentivirus transfection and resistance selection (Supporting Information Fig. S4A, B) . GFP1 cell populations in KIAA1199-downregulated HCT116 stable cell line and the negative control cell line remain stable during cell passaging and thawing, indicating that cell transfection efficiency was sustained (Supporting Information Fig.  S4 ). Cells were injected into NOD/SCID mice via tail veins. As a result, mice in KIAA1199-downregulated group developed less and smaller lung metastases than negative control group (Fig. 3a) . Moreover, lung metastases were determined by hematoxylin and eosin (H&E) staining, as shown in Figure 3b staining results confirmed the results of Figure 3a . In addition, body weight curve was shown in Figure 3c . IHC analyses (Fig.  3d) confirmed downregulation of KIAA1199 expression within tumor tissue, which further support the conclusion that endogenous expression of KIAA1199 induced tumor metastasis. We also detected EMT markers in mice lung metastases. As illustrated in Figure 3d E-cadherin expression in KIAA1199-downregulated group was significantly higher than negative control group, while vimentin was significantly lower, indicating that endogenous expression of KIAA1199 could indeed induce EMT in vivo. These results demonstrated that downregulation of KIAA1199 reduced metastasis in CRC.
KIAA1199 was a direct target of miR-216a
To elucidate the upstream microRNAs which regulate the expression of KIAA1199, we performed biological information analysis (TargetScan and miRanda), and identified two putative binding sites for miR-216a and one putative binding site for miR-128 and miR-124 each in the 3 0 -UTR of KIAA1199 mRNA. Specific positions and sequences were shown in Figure 4a . We quantified mRNA levels of these three microRNAs in CRC cells through taqman real-time PCR, as illustrated in Figures 2a and 4b , KIAA1199 was overexpressed in CRC cells compared with human normal colon epithelial cell (FHC), which was accompanied by correspondingly downregulation of miR-216a. KIAA1199 expression was negative correlated with miR-216a (Supporting Information Table S8 ), and the negative correlation between miR-216a and KIAA1199 was futher demonstrated in CRC tumor tissues (Supporting Information Fig. S5A ). Consequently, we chose miR-216a for further investigation.
To experimentally confirm that KIAA1199 expression was regulated by miR-216a, we overexpressed miR-216a in 5 CRC cells by transfecting miR-216a mimic (Supporting Information Fig. S5B ). As expected, overexpression of miR-216a reduced KIAA1199 expression in both mRNA and protein levels in CRC cells (Figs. 4c and 4d) , and the reduction of KIAA1199 protein by miR-216a was also confirmed by immunofluorescence staining (Supporting Information Fig.  S5C ). Moreover, KIAA1199 expression was rescued while miR-216a expression was down-regulated by transfecting miR-216a inhibitor in CRC cells (Supporting Information  Fig. S5D ). In luciferase reporter assays, as shown in Figure 4e (top), we constructed luciferase reporter plasmid by cloning the predicted binding sites of KIAA1199 3 0 -UTR and miR216a in the downstream of the firefly luciferase gene. The conserved site (position 633-640 bp) was chosen between the two putative binding sites (Supporting Information Table S9 ). We observed that cotransfection of the luciferase reporter plasmid and miR-216a mimic resulted in reduced luciferase activity, while mutation of the binding site abrogated the effect of miR-216a (Fig. 4e) . These results suggested that KIAA1199 was a direct target of miR-216a.
Overexpression of miR-216a suppresses migration and invasion of CRC cells in vitro and tumor metastasis in vivo
To unravel the role of miR-216a in CRC metastasis, we overexpressed miR-216a in CRC cells. Notably, overexpression of miR-216a significantly repressed the migration, invasion and 3D invasion of HCT116 and LOVO cells (Fig. 1f and Supporting Information Fig. S5E, F) . Additionally, migration, invasion and 3D invasion were rescued by overexpression of KIAA1199 in the miR-216a overexpressed cells (Figs. 4g and  4h and Supporting Information Fig. S5F, G) . These results testified the inhibited effect of miR-216a on migration and invasion of CRC cells.
To further investigate the function of miR-216a on CRC metastasis in vivo, cells overexpressing miR-216a were injected into NOD/SCID mice via tail veins. It was found that, mice in miR-216a group developed less and smaller lung metastases than control group (Fig. 5a) . Moreover, as shown in Figure 5b staining results confirmed the results of Figure 5a . In addition, body weight curve was shown in Figure 5c . IHC analyses (Fig.  5d) confirmed downregulation of KIAA1199 expression within tumor tissue, which further indicated that downregulation of KIAA1199 by miR-216a decreased tumor metastasis. EMT markers in mice lung metastases were also detected. As illustrated in Figure 5d E-cadherin expression in miR-216a group was significantly higher than control group, while vimentin was significantly lower, indicating that miR-216a could reversed EMT induced by KIAA1199 in vivo. These results demonstrated that downregulation of KIAA1199 by miR-216a suppressed metastasis in CRC.
Discussion
The key findings of the current research are the elucidation of the pathological role of KIAA1199 in CRC metastasis and the exploration of the microRNAs upstream of KIAA1199. We show that elevated levels of KIAA1199 are existed in both CRC cell lines and tissues, and positively correlated with tumor invasion depth, TNM stage, poor clininal prognosis and numbers and mesenchymal phenotype of CTCs/CTM. Furthermore, we demonstrate that down-regulation of KIAA1199 suppresses migration and invasion of CRC cells in vitro, inhibits metastasis in vivo, and KIAA1199 was a direct and functional target of miR-216a.
The clinical prognosis of CRC mainly depends on the stage, and dramatic difference in prognosis has been observed between early stage and advanced CRC patients. 3, 4 Metastasis is considered to be the leading cause of treatment failure in CRC, in which CSC plays a crucial role. 9 However, little is known about the potential molecular mechanism of CSC involved in the metastatic process. We demonstrate that many genes are highly expressed in CD441 cancer stem-like cells from metastatic than primary CRC tissues, including KIAA1199. Consistent with the previous researches, we also find that high expression of KIAA1199 correlated well with tumor invasion depth, TNM stage and PFS 32, 33 . CTCs/CTM plays an important role in hematogenous metastasis of CRC. Sensitive and specific detection of CTCs/ CTM remains a challenge in clinical oncology. CTCs isolation technologies using epithelial cell adhesion molecule (EpCAM)-based platforms were unable to detect CTCs/CTM displaying a mesenchymal phenotype, which were believed to have an increased metastatic potential. 24, 34 Cytopathologic identification of CTCs/CTM by size of epithelial tumor cell (ISET) was proved to be a promising method, which needs to be complemented by immunological and molecular studies for further characterization. 35, 36 Here, we capture CTCs/CTM through ISET method and perfrom further identification by Romanowsky and IF staining. We demonstrated that KIAA1199 expression was significantly correlated with numbers and mesenchymal phenotype of CTCs/CTM. One limitation of this study is the small sample size, requiring future expansion to confirm the discovery.
KIAA1199 was initially reported to be an inner-ear gene expressed in Deiters' cells and the fibrocytes, the mutation of which will result in nonsyndromic hearing loss. 37 Recently, several researches suggested that KIAA1199 was a cellmigration inducing protein (CEMIP) that was associated with migration and invasion of tumor cells and poor clinical prognosis in many cancers. 31, [38] [39] [40] [41] Nevertheless, the exact function of KIAA1199 in CRC metastasis was still unknown. Here, we discover for the first time that down-regulation of endogenous KIAA1199 reduce EMT, leading to a decreased migratory and invasive capacity of CRC cells. Subsequent gain-offunction experiments further validate these findings. In line with these observations, diminished lung metastasis and EMT are observed in mice intravenously injected with KIAA1199-downregulated CRC cells. These observations strengthen the conclusion that KIAA1199 played a key role in retaining an aggressive phenotype of CRC cells, and suppression of KIAA1199-related motilities of tumor cells efficiently reduced tumor metastasis in CRC.
It has been reported that KIAA1199 was upregulated in invasive breast cancer. By mediating calcium leakage of endoplasmic reticulum, KIAA1199 could increase cytosolic calcium and then activate PKCa/Ras/MEK1/2/ENK1/2 signal pathway, ultimately leading to increased cell migration. 31 Another report showed that KIAA1199 is highly expressed in HPV-positive cells, and KIAA1199 enhanced EGF-mediated EMT by promoting EGFR stability and phosphorylations of EGF-dependent Src, MEK1 and ERK1/2 in cervical cancer. 41 Fink SP discovered that KIAA1199 overexpression correlated with poor outcome in colon cancer, and participated in degradation of hyaluronan (HA) in extracellular matrix, which will endow the tumor with an aggressive phenotype. 33 All these researches reported downstream regulation mechanism of KIAA1199. Concerning upstream regulators of KIAA1199, 42 hypoxia inducible factor-2a (HIF-2a) was reported to promote cell migration in colon cancer through directly binding to the promoter and increasing KIAA1199 expression.
Recently, miRNAs have been indicated to be involved in tumor metastasis. 43 miR-216a was reported to participate in the development of acute pancreatitis, 44, 45 and was downregulated in pancreatic cancer, which may inhibit pancreatic tumor growth by directly targeting Janus kinase 2 (JAK2). 46 It has been shown that miR-216a function as tumor suppressor gene in pancreatic cancer 46 and oral squamous cell carcinoma, 47 while as tumor-promoting gene in hepatocellular carcinoma 48, 49 and prostate cancer. 50 Hitherto, the expressions and function of miR-216a in CRC have not been reported yet. Here, we have demonstrated for the first time that miR-216a suppressed KIAA1199 expression in mRNA and protein level, and down-regulation of KIAA1199 by miR-216a decreases migration and invasion of CRC cells in vitro and tumor metastases in vivo. Besides, KIAA1199 expression had negative correlation with that of miR-216a in CRC cells.
In conclusion, the present research establishes KIAA1199 as a potential biomarker for CRC prognosis as well as a novel target for preventing metastasis. Mechanistic researches of KIAA1199 in CRC metastasis, especially downstream signal pathways await further investigations.
